Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice

Neurobiology of Disease

Volumn 28, Issue 2, 2007, Pages 197-205

  Domenici, M R ^a   Scattoni, M L ^a   Martire, A ^a   Lastoria, G ^a   Potenza, R L ^a   Borioni, A ^a   Venerosi, A ^a   Calamandrei, G ^a   Popoli, P ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Adenosine A2A receptor antagonist; Behavior; Electrophysiology; Huntington's disease; R6 2 mice

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BRAIN CORTEX; BRAIN PROTECTION; BRAIN SLICE; CONTROLLED STUDY; COORDINATION DISORDER; CORPUS STRIATUM; DRUG EFFECT; ELECTROPHYSIOLOGY; EMOTION; EXPERIMENTAL MODEL; FEMALE; HUNTINGTON CHOREA; MAZE TEST; MOTOR COORDINATION; MOUSE; NEUROPATHOLOGY; NEUROTOXICITY; NOCICEPTIVE STIMULATION; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID AGONISTS; GLUTAMIC ACID; HUNTINGTON DISEASE; LEARNING DISORDERS; MAZE LEARNING; MENTAL DISORDERS; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; ORGAN CULTURE TECHNIQUES; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; TRIAZOLES;

EID: 35348983910     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.07.009     Document Type: Article

References (47)

1. Anderson W.W., and Collingridge G.L. The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J. Neurosci. Methods 15 (2001) 71-83
2. 2a adenosine antagonists. J. Med. Chem. 39 (1996) 1164-1171
3. Beal M.F., Ferrante R.J., Swartz K.J., and Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11 (1991) 1649-1659
4. Behrens P.F., Franz P., Woodman B., Lindenberg K.S., and Landwehrmeyer G.B. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125 (2002) 1908-1922
5. 2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J. Neurosci. 23 (2003) 5361-5369
6. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 19 (1999) 3248-3257
7. Cepeda C., Marjorie A.A., Calvert C.R., Flores-Hernandez J., Chandler S.H., Leavitt B.R., Hayden M.R., and Levine M.S. NMDA receptor function in mouse models of Huntington's disease. J. Neurosci. Res. 66 (2001) 525-539
8. Cha J.J., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney J.B., Davies S.W., Bates G.P., and Young A.B. Altered neurotransmitter receptor expression in transgenic mouse model of Huntington's disease. Philos. Trans. R. Soc. Lond., B 354 (1999) 981-989
9. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19 (1999) 9192-9200
10. 2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J. Biol. Chem. 280 (2005) 14331-14340
11. Chou S.Y., Lee Y.C., Chen H.M., Chiang M.C., Lai H.L., Chang H.H., Wu Y.C., Sun C.N., Chien C.L., Lin Y.S., Wang S.C., Tung Y.Y., Chang C., and Chern Y. CGS 21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 93 (2005) 310-320
12. 2A receptor blockade of beta-amyloid neurotoxicity. Br. J. Pharmacol. 138 (2003) 1207-1209
13. El Yacoubi M., Costentin J., and Vaugeois J.M. Adenosine A2A receptor and depression. Neurology 61 11 Suppl 6 (2003) S82-S87
14. Ferrè S., Fredholm B.B., Morelli M., Popoli P., and Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20 (1997) 482-487
15. File S.E., Mahal A., Mangiarini L., and Bates G.P. Striking changes in anxiety in Huntington's disease transgenic mice. Brain Res. 805 (1998) 234-240
16. 2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J. Neurochem. 88 (2004) 538-544
17. 2A receptors reduces transmitter outflow. Neurobiol. Dis. 17 (2004) 77-88
18. Glass M., Dragunow M., and Faull R.L.M. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97 (2000) 505-519
19. Halldner L., Lozza G., Lindstrom K., and Fredholm B.B. Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist. Eur. J. Pharmacol. 406 (2000) 345-354
20. Hamilton J.M., Salmon D.P., Corey-Bloom J., Gamst A., Paulsen J.S., Jerkins S., Jacobson M.W., and Peavy G. Behavioural abnormalities contribute to functional decline in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 74 (2003) 120-122
21. Hantraye P., Riche D., Maziere M., and Isacson O. A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp. Neurol. 108 (1990) 91-104
22. Hickey M.A., Reynolds G.P., and Morton A.J. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J. Neurochem. 81 (2002) 46-59
23. Hickey M.A., Gallant K., Gross G.G., Levine M.S., and Chesselet M.F. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol. Dis. 20 (2005) 1-11
24. Hockly E., Cordery P.M., Woodman B., Mahal A., Van Dellen A., Blakemore C., Lewis C.M., Hannan A.J., and Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 51 (2002) 235-242
25. Johnson M.A., Rajan V., Miller C.E., and Wightman R.M. Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease. J. Neurochem. 97 (2006) 737-746
26. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.F., and Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol. 86 (2001) 2667-2677
27. Luthi-Carter R., Apostol B.L., Dunah A.W., DeJohn M.M., Farrell L.A., Bates G.P., Young A.B., Staendert D.G., Thompson L.M., and Cha J.H. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins and phosphorilation. Neurobiol. Dis. 14 (2003) 624-636
28. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.v., and Bates J.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
29. Martire A., Calamandrei G., Felici F., Scattoni M.L., Lastoria G., Domenici M.R., Tebano M.T., and Popoli P. Opposite effects of the A(2A) receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice. Neurosci. Lett. 417 (2007) 78-83
30. Noldus L.P., Trienes R.J., Hendriksen A.H., Jansen H., and Jansen R.G. The Observer Video-Pro: new software for the collection, management, and presentation of time-structured data from videotapes and digital media files. Behav. Res. Methods Instrum. Comput. 32 (2000) 197-206
31. 2A receptors in neuroprotection of dopaminergic neurons. Neurology 61 11 Suppl. 6 (2003) S49-S50
32. 2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22 (2002) 1967-1975
33. 2A receptors. Neurology 61 11 Suppl 6 (2003) S69-S71
34. 2A receptor antagonism and neuroprotection: mechanisms, lights, and shadows. Crit. Rev. Neurobiol. 16 (2004) 99-106
35. 2A receptors in Huntington's disease. Prog. Neurobiol. 81 (2007) 331-348
36. 2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease. Behav. Brain Res. 176 (2007) 216-221
37. Shin J.Y., Fang Z.H., Yu Z.X., Wang C.E., Li S.H., and Li X.J. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 171 (2005) 1001-1012
38. Starling A.J., André V.M., Cepeda C., de Lima M., Chandler S.H., and Levine M.S. Alterations in N-methyl-d-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J. Neurosci. Res. 82 (2005) 377-386
39. 2A receptors. Progr. Neurobiol. 59 (1999) 355-396
40. Tarditi A., Camurri A., Varani K., Borea P.A., Woodman B., Bates G., Cattaneo E., and Abbracchio M.P. Early and transient alteration of adenosine A(2A) receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis. 23 (2006) 44-53
41. Tebano M.T., Domenici M.R., and Popoli P. SCH 58261 differentially influences quinolinic acid-induced effects in striatal and in hippocampal slices. Eur. J. Pharmacol. 450 (2002) 253-257
42. Tebano M.T., Pintor A., Frank C., Domenici M.R., Martire A., Pepponi R., Potenza R.L., Grieco R., and Popoli P. Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum. J. Neurosci. Res. 77 (2004) 100-107
43. 2A receptor signaling in striatal cells expressing mutant Huntingtin. FASEB J. 15 (2001) 1245-1247
44. Varani K., Abbracchio M.P., Cannella M., Cislaghi G., Giallonardo P., Mariotti C., Cattabriga E., Cattabeni F., Borea P.A., Squitieri F., and Cattaneo E. Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. FASEB J. 17 (2003) 2148-2150
45. Walker Francis O. Huntington's disease. Lancet 369 (2007) 218-228
46. Wilcox R.G. New Statistical Procedures for the Social Sciences. Modern Solutions to Basic Problems (1987), Lawrence Erlbaum, Hillsdale, NJ
47. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., and Raymond L.A. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860